A vaccine for human babesiosis: prospects and feasibility

No Thumbnail Available
File version
Author(s)
Al-Nazal, H
Low, L
Kumar, S
Good, MF
Stanisic, DI
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
License
Abstract

Babesiosis is a tick-borne disease caused by intraerythrocytic Babesia parasites. It is a well-known illness in companion animals and livestock, resulting in substantial economic losses in the cattle industry. Babesiosis is also recognized as an emerging zoonosis of humans in many countries worldwide. There is no vaccine against human babesiosis. Currently, preventive measures are focused on vector avoidance. Although not always effective, treatment includes antimicrobial therapy and exchange transfusion. In this review, we discuss the host's immune response to the parasite, vaccines being used to prevent babesiosis in animals, and lessons from malaria vaccine development efforts to inform the development of a human babesiosis vaccine. An effective human vaccine would be a significant advance towards curtailing this rapidly emerging disease.

Journal Title

Trends in Parasitology

Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note

This publication has been entered in Griffith Research Online as an advanced online version.

Access the data
Related item(s)
Subject

Biological sciences

Veterinary sciences

Medical microbiology

Babesia

babesiosis

human vaccine

immunity

Persistent link to this record
Citation

Al-Nazal, H; Low, L; Kumar, S; Good, MF; Stanisic, DI, A vaccine for human babesiosis: prospects and feasibility, Trends in Parasitology, 2022

Collections